SCHEMBL159497

SCHEMBL159497

CCNC(=O)c1ccnc([O])n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.46
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RIPK1 Q13546 1/20 0.38
PARP1 P09874 2/20 0.38
HPGDS O60760 1/20 0.37
CHIA Q9BZP6 1/20 0.37
CA1 P00915 1/20 0.36
GAA P10253 1/20 0.36
CA9 Q16790 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
BRD4 O60885 1/20 0.36
RAB9A P51151 1/20 0.36
ABL1 P00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161009 0.87 NPC1 (0.45) KDM4ELMNAL3MBTL1RIPK1GAA
SCHEMBL163044 0.84 KDM4E (0.50) KDM4ELMNAHTTNPSR1NPC1
SCHEMBL159528 0.82 RAB9A (0.47) KDM4ELMNAHTTGAANPSR1
SCHEMBL163380 0.80 BRD4 (0.42) CNR1KDM4ELMNAGAAHSD17B10
SCHEMBL165605 0.78 KMT2A (0.45) KDM4EHTTL3MBTL1HSD17B10NPC1
SCHEMBL160293 0.76 ANO1 (0.42)
SCHEMBL162424 0.76 PARP1 (0.45) CNR1KDM4ELMNAHTTL3MBTL1
SCHEMBL158412 0.76 CNR1 (0.46) CNR1KDM4EHTTRIPK1PARP1
SCHEMBL19661316 0.76 LMNA (0.56) CNR1KDM4ELMNAHTTL3MBTL1
SCHEMBL17844425 0.74 P2RX7 (0.66) CNR1KDM4ELMNAHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 CNR1 3934/4885KDM4E 2214/4885LMNA 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.